Doravirine, lamivudine, and tenofovir and Lefamulin Tablets
Determining the interaction of Doravirine, lamivudine, and tenofovir and Lefamulin Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. When oral lefamulin was administered with oral rifampin, a potent CYP450 3A4/P-gp inducer, mean lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 57% and 72%, respectively. Coadministration of intravenous lefamulin with oral rifampin reduced mean lefamulin Cmax and AUC by 8% and 28%, respectively. The interaction has not been studied with other, less potent inducers. MANAGEMENT: The potential for diminished pharmacologic effects of lefamulin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected. References "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Professional:MONITOR: Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. When oral lefamulin was administered with oral rifampin, a potent CYP450 3A4/P-gp inducer, mean lefamulin peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 57% and 72%, respectively. Coadministration of intravenous lefamulin with oral rifampin reduced mean lefamulin Cmax and AUC by 8% and 28%, respectively. The interaction has not been studied with other, less potent inducers.
MANAGEMENT: The potential for diminished pharmacologic effects of lefamulin should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.
- "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.
Generic Name: doravirine / lamivudine / tenofovir
Brand name: Delstrigo
Synonyms: Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate
Generic Name: lefamulin
Brand name: Xenleta
Synonyms: Lefamulin Injection, Lefamulin, Lefamulin (oral/injection)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Doravirine, lamivudine, and tenofovir-Leflunomide
- Doravirine, lamivudine, and tenofovir-Legatrin PM
- Doravirine, lamivudine, and tenofovir-Lemtrada
- Doravirine, lamivudine, and tenofovir-Lenalidomide
- Doravirine, lamivudine, and tenofovir-Lenvatinib
- Doravirine, lamivudine, and tenofovir-Lenvatinib Mesylate
- Lefamulin Tablets-Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate
- Lefamulin Tablets-Doribax
- Lefamulin Tablets-Doripenem
- Lefamulin Tablets-Doripenem Intravenous
- Lefamulin Tablets-Dornase Alfa
- Lefamulin Tablets-Dornase alfa inhalation